1. Home
  2. MNPR vs CPSS Comparison

MNPR vs CPSS Comparison

Compare MNPR & CPSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MNPR
  • CPSS
  • Stock Information
  • Founded
  • MNPR 2014
  • CPSS 1991
  • Country
  • MNPR United States
  • CPSS United States
  • Employees
  • MNPR N/A
  • CPSS N/A
  • Industry
  • MNPR Biotechnology: Pharmaceutical Preparations
  • CPSS Finance: Consumer Services
  • Sector
  • MNPR Health Care
  • CPSS Finance
  • Exchange
  • MNPR Nasdaq
  • CPSS Nasdaq
  • Market Cap
  • MNPR 250.0M
  • CPSS 225.2M
  • IPO Year
  • MNPR 2019
  • CPSS 1992
  • Fundamental
  • Price
  • MNPR $40.25
  • CPSS $10.52
  • Analyst Decision
  • MNPR Strong Buy
  • CPSS
  • Analyst Count
  • MNPR 4
  • CPSS 0
  • Target Price
  • MNPR $43.00
  • CPSS N/A
  • AVG Volume (30 Days)
  • MNPR 71.2K
  • CPSS 29.4K
  • Earning Date
  • MNPR 03-27-2025
  • CPSS 03-14-2025
  • Dividend Yield
  • MNPR N/A
  • CPSS N/A
  • EPS Growth
  • MNPR N/A
  • CPSS N/A
  • EPS
  • MNPR N/A
  • CPSS 0.87
  • Revenue
  • MNPR N/A
  • CPSS $184,246,000.00
  • Revenue This Year
  • MNPR N/A
  • CPSS N/A
  • Revenue Next Year
  • MNPR N/A
  • CPSS $17.21
  • P/E Ratio
  • MNPR N/A
  • CPSS $12.11
  • Revenue Growth
  • MNPR N/A
  • CPSS N/A
  • 52 Week Low
  • MNPR $1.72
  • CPSS $7.03
  • 52 Week High
  • MNPR $54.30
  • CPSS $12.73
  • Technical
  • Relative Strength Index (RSI)
  • MNPR 49.34
  • CPSS 38.44
  • Support Level
  • MNPR $38.80
  • CPSS $10.70
  • Resistance Level
  • MNPR $45.60
  • CPSS $11.67
  • Average True Range (ATR)
  • MNPR 5.19
  • CPSS 0.47
  • MACD
  • MNPR -1.50
  • CPSS -0.08
  • Stochastic Oscillator
  • MNPR 9.37
  • CPSS 0.00

About MNPR Monopar Therapeutics Inc.

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicin for the treatment of soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.

About CPSS Consumer Portfolio Services Inc.

Consumer Portfolio Services Inc is a U.S.-based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent, by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.

Share on Social Networks: